Acute Bacterial Skin & Skin Structure Infection Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market is Segmented by Type of Infection (Hospital-acquired ABSSI and Community-acquired ABSSI), Route of Administration (Oral, Parenteral, and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (USD million) for the above segments.

Acute Bacterial Skin & Skin Structure Infection Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Acute Bacterial Skin and Skin Structure Infection Industry Overview

The acute bacterial skin and skin structure infection market is moderately competitive. The market comprises many small and large market players. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at lower prices. Some of the market players are Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc.

Acute Bacterial Skin and Skin Structure Infection Market Leaders

  1. Paratek Pharmaceuticals, Inc.,

  2. Melinta Therapeutics, Inc.,

  3. Merck & Co., Inc.,

  4. Pfizer Inc

  5. AbbVie Inc

  6. *Disclaimer: Major Players sorted in no particular order
absssi.png

ABSSSI Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?